Precigen Aligns Executive Incentives with FDA Approval Goals

An announcement from Precigen (PGEN) is now available.

Precigen, Inc. has incentivized its key employees, including top executives, with performance stock units (PSUs) which vest on reaching critical operational goals, aligning their interests with long-term shareholder value. These PSUs, part of the 2023 Omnibus Incentive Plan, will vest based on the submission and FDA approval of a Biologics License Application for a specific investigational product by the end of 2026. Vesting is contingent on continued employment and certain termination conditions, with provisions for accelerated vesting in the event of a change in control.

See more data about PGEN stock on TipRanks’ Stock Analysis page.